Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
Retrieved on:
Thursday, June 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Prostate cancer, Accurin, Targeted Alpha Therapies (TAT) at Bayer, Prostate Cancer at Bayer, Xofigo® (radium Ra 223 dichloride) Injection, NUBEQA® (darolutamide)3, Bayer, Noria Therapeutics (Noria) / PSMA Therapeutics Inc., TARGETED ALPHA THERAPIES (TAT) AT BAYER, PROSTATE CANCER AT BAYER, XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, NUBEQA® (DAROLUTAMIDE)3, BAYER, NORIA THERAPEUTICS (NORIA) / PSMA THERAPEUTICS INC.
Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
Key Points:
- Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
- Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus for Bayer.
- About Noria Therapeutics (Noria) / PSMA Therapeutics Inc.
Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics and theranostic agents. - PSMA Therapeutics Inc. is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.